| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study
|
Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; ANN-LII CHENG; Lai M.-S.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:39Z |
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)
|
Kuo S.-H.; Tsai H.-J.; Lin C.-W.; Yeh K.-H.; Lee H.-W.; Wei M.-F.; Shun C.-T.; Wu M.-S.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:39Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:39Z |
Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL
|
Kuo S.-H.; Chen L.-T.; Lin C.-W.; Yeh K.-H.; Shun C.-T.; Tzeng Y.-S.; Liou J.-M.; Wu M.-S.; Hsu P.-N.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer
|
Tsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; ANN-LII CHENG; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Corrigendum to ��Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells�� [Neoplasia (United States) 14 (2012) 463�V475](S1476558612801023)(10.1596/neo.12300)
|
Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG; Chen C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
|
Meyer T.; Palmer D.H.; ANN-LII CHENG; Hocke J.; Loemb? A.-B.; Yen C.-J. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients
|
Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
|
Yang S.-H.; Lee J.-C.; Guo J.-C.; Kuo S.-H.; Tien Y.-W.; Kuo T.-C.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; ANN-LII CHENG; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
|
Bruix J.; ANN-LII CHENG; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
|
Chen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Shao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
The HER2 inhibitor lapatinib potentiates doxorubicininduced cardiotoxicity through iNOS signaling
|
Hsu W.-T.; Huang C.-Y.; Yen C.Y.T.; ANN-LII CHENG; Hsieh P.C.H. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
|
Bouattour M.; Raymond E.; Qin S.; ANN-LII CHENG; Stammberger U.; Locatelli G.; Faivre S. |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Reply to: ��Predictors of sorafenib benefit in patients with hepatocellular carcinoma��
|
Bruix J.; ANN-LII CHENG; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice
|
Tsai C.-L.; Liu W.-L.; Hsu F.-M.; Yang P.-S.; Yen R.-F.; Tzen K.-Y.; ANN-LII CHENG; Chen P.-J.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Chang C.-J.; Yang Y.-H.; Chiu C.-J.; Lu L.-C.; Liao C.-C.; Liang C.-W.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Adiposity, inflammation, and breast cancer pathogenesis in Asian Women
|
Iyengar N.M.; Chen I.-C.; Zhou X.K.; Giri D.D.; Falcone D.J.; Winston L.A.; Wang H.; Williams S.; Lu Y.-S.; Hsueh T.-H.; ANN-LII CHENG; Hudis C.A.; Lin C.-H.; Dannenberg A.J. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-�eB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells
|
Wu C.-H.; Yang Y.-H.; Chen M.-R.; Tsai C.-H.; ANN-LII CHENG; Doong S.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
The APPLE Association President's Message
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Effect of glucocorticoid use on survival in patients with stage I�VIII breast cancer
|
Lin C.-H.; Chuang P.-Y.; You S.-L.; Chiang C.-J.; Huang C.-S.; Wang M.-Y.; Chao M.; Lu Y.-S.; ANN-LII CHENG; Tang C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
|
Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:26Z |
The APPLE Association President's Message
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:26Z |
Corrigendum to ��Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies�� [J hepatol 67 (2017) 999�V1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))
|
Bruix J.; ANN-LII CHENG; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:26Z |
Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer
|
Chen W.-Y.; Wu C.-T.; Wang C.-W.; Lan K.-H.; Liang H.-K.; Huang B.-S.; Chang Y.-L.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:26Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
The APPLE association president's message
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C. |
